Immunotherapy for sarcomas: new frontiers and unveiled opportunities

Harsimrat Kaur Birdi,1,2,3 Anna Jirovec,1,2,3 Serena Cortés-Kaplan,1,2,3 Joel Werier,4,5 Carolyn Nessim,1,5 Jean-Simon Diallo,1,2,3 Michele Ardolino 1,2,3

ABSTRACT
Sarcomas are a rare malignancy of mesenchymal tissues, comprising a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades and, although effective in early disease (stages I–II), in later stages, where metastatic tumors are present, these treatments are less effective. Given the spectacular results obtained by cancer immunotherapy in a variety of solid cancers and leukemias, there is now a great interest in applying this new realm of therapy for sarcomas. The widespread use of immunotherapy for sarcoma relies on immuno-profiling of subtypes, immunomonitoring for prognosis, preclinical studies and insight into the safety profile of these novel therapies. Herein, we discuss preclinical and clinical data highlighting how immunotherapy is being used in soft tissue sarcoma and bone sarcomas.

INTRODUCTION
Sarcoma is a rare disease of tissues of mesenchymal origin encompassing bone, fat, joint and muscle,1 divided in two major types: >50 subtypes of soft-tissue sarcoma (STS) and three major subtypes of bone sarcoma (osteosarcoma, chondrosarcoma and Ewing’s (EW) sarcoma).2,3 Although rare in adults (annual incidence <1%), sarcomas account for 20% of all pediatric cancers in North America.4 Despite its heterogeneous origins, histology and genetic markers, a common feature of sarcoma is a poor prognosis in patients with advanced disease. Although survival rates for broad sarcoma subtypes are difficult to ascertain due to disease heterogeneity, in general, patients with localized disease benefit from radiotherapy and surgery (5-year survival rate >80% in STS patients and ~70% in bone sarcoma patients). However, patients exhibiting stage III/IV STS or various bone sarcomas have 5-year survival rates of <20% and between 22% and 57%, respectively.4–6 Additionally, disease relapse, which occurs in 40%–60% of high grade cases, is not uncommon.7 Despite recent advancements in testing, diagnosis, molecular characterization and combination chemotherapies, there has been little progress in improving outcomes in an advanced disease setting.

Cancer immunotherapy has progressed exponentially in recent decades, owing greatly to an improved understanding of the interplay between the immune system and cancer. Immunotheapies such as adoptive cell transfer, oncolytic viruses (OVs) and immune checkpoint blockade (ICB) show promise for the future of sarcoma therapy. However, therapies that have gained traction for the treatment of other cancer types encounter challenges in sarcoma due to: (1) a lack of well established antigens in subtypes that can be targeted by vaccines, therapeutic antibodies or chimeric antigen receptors (CAR) therapy, (2) presence of extensive tumor immune functions. Mono-clonal antibodies targeting CTLA-4, PD-1, PD-L1, LAG-3, TIM-3 and VISTA.8 ICB is used to block receptor-ligand interactions in order to restore anti-tumor immune functions. Monoclonal antibodies targeting CTLA-4, PD-1 and PD-L1 received Food and Drug Administration (FDA)-approval in cancer.9

Expression of checkpoint receptors varies widely in sarcoma patients and according to subtype.10–13 A study evaluating 1072 sarcoma specimens found that PD-1 and PD-L1 were expressed in only 10% and 22% of cases, meanwhile LAG-3 and TIM-3 were expressed in 42% and 54% of cases, respectively.14 A higher expression of checkpoint receptors was observed in non-translocation-associated sarcomas, such as dedifferentiated...
liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma and leiomyosarcoma, than translocation-associated sarcomas. Other groups have also shown that UPS, leiomyosarcoma and LPS patients have increased expression of PD-1/PD-L1, suggesting that these sarcoma subtypes could potentially respond to ICB treatment.

Several individual case reports have shown that sarcoma patients treated with ICB achieve a positive response or complete remission. All patients presented with unique sarcoma subtypes and with varying levels of checkpoint receptor expression, thus identifying commonalities between the positive responses was challenging. The SARC028 (NCT02301039) was one of the first multicenter phase II trials evaluating the effectiveness of ICB in sarcoma. This study comprised of 80 evaluable patients, 40 with STS and 40 with bone sarcoma that were treated with pembrolizumab (anti-PD-1). Response to therapy was limited to patients in the STS cohort with seven patients showing an objective response rate, with greater benefit in UPS and DDLPS patients, whereas little to no benefit in the bone sarcoma cohort was observed. Tumor biopsies before and during treatment were obtained from patients enrolled in the SARC028 trial to characterize immune features associated with treatment response. At baseline, higher density of tumor-infiltrating T cells and TAMs expressing PD-L1 were observed in responders versus non-responders. Sarcoma immune class (SIC) classifications of patients confirmed that tumors in the immune high class (SIC E) showed the most benefit in response to pembrolizumab. To further investigate the effectiveness of pembrolizumab treatment in patients with STS, the SARC028 study enrolled an expansion cohort to include additional patients; 40 with UPS and 40 with LPS. The UPS cohort reached its primary endpoint, with an objective response rate in 9/40 patients (two complete and seven partial responses). The LPS group had an objective response rate in 4/39 patients (four partial responses).

The Alliance A091401 study (NCT02500797) evaluated the effectiveness of nivolumab (anti-PD-1) alone or in combination with ipilimumab (anti-CTLA-4) for the treatment of unresectable and metastatic sarcoma, where 2/38 patients in the nivolumab group and 6/38 patients in the combination group responded. These responses were observed in patients with leiomyosarcoma, UPS, myxofibrosarcoma, angiosarcoma, alveolar soft part sarcoma (ASPS) and malignant fibrous histiocytoma. The clinical benefit of nivolumab monotherapy (median PFS 2 months) was below that of standard chemotherapy and the combination of nivolumab and ipilimumab (median PFS 4 months) was on par with currently available chemotherapy. Three expansion cohorts for UPS, DDLPS and gastrointestinal stromal tumor were subsequently enrolled for the A091401 study. Only the combination arm for UPS and DDLPS met the primary endpoint (6 months confirmed response rate). Correlative analyses for genomic and clinical biomarkers and response is currently underway.

Based on the results from the SARC028 trial, another group has begun to recruit patients with UPS and LPS to evaluate the effectiveness of ICB in neoadjuvant settings. In this phase II, single-center, open-label, randomized non-comparative trial (NCT03307616), patients will receive nivolumab (anti-PD-1) alone or in combination with ipilimumab (anti-CTLA-4) before surgery. The UPS cohort will also receive standard of care radiation therapy for UPS in the trunk/extremities. Interestingly, radiation therapy in UPS increased tumor infiltrating immune cells and tumor PD-L1 expression opening an opportunity to use PD-1/L1 blockade. Preliminary results from 24 evaluable patients (9 UPS and 14 LPS) show a median pathological response of 95% in the UPS cohort and 22.5% in the LPS cohort. This study is still recruiting and will also include transcriptome, immune and microbiome profiling, which will provide much needed information about the immune response in sarcoma and the molecular mechanisms that promote/hinder the response to ICB in UPS and LPS. So far, these highlighted studies show that UPS and LPS are responsive to ICB. These tumors have an increased amount of tumor infiltrating immune cells and expression of PD-1/PD-L1 which could be a contributing factor their responsiveness.

ICB has been also combined with chemotherapy or targeted therapy. A phase I/II trial (NCT02888665) assessed the efficacy of pembrolizumab plus doxorubicin in patients with metastatic and/or unresectable sarcoma. Although, this study did not meet its primary response rate endpoint, the combination therapy was well tolerated and doubled the median progression-free survival. A phase II study (NCT02636725) evaluated the efficacy of combining pembrolizumab and axitinib, a VEGFR inhibitor, in patients with advanced metastatic sarcoma. 65.6% of treated patients met the primary endpoint (3 months progression-free survival) with most responses occurring in patients with ASPS. Notably, tumor biopsies from ASPS patients showed high tumor infiltrating lymphocyte (TIL) infiltration and PD-L1 expression, suggesting a ‘hot’ immune phenotype. This could potentially explain why ASPS responded to ICB, when typically tumors with low mutational burden such as ASPS are associated with poor ICB responsiveness. These studies highlight the need for improved treatment for patients with advanced metastatic and unresectable sarcomas.

**Adoptive cell therapy**

**T cells**

Adoptive cell therapy (ACT) involves the extraction of immune cells from a patient, or from healthy donors, which are then manipulated ex vivo and expanded prior to reinfection in the patient. Promising results in hematological and some solid malignancies have been achieved by using T cells transduced with vectors encoding T cell receptors (TCRs) recognizing HLA I-restricted antigens or CARs recognizing cell surface proteins. In both cases, the antigen recognized by the exogenous TCR or CAR is expressed uniquely, or preferentially, by tumor
cells (figure 1). This represents a major obstacle in the expansion of these therapeutic strategies for sarcoma, as these tumors are highly heterogeneous and, as such, also vary greatly in their antigenic landscape both between subtypes and within a single disease.

Expression of cancer testis antigens (CTAs), including MAGE, NY-ESO-1 and SSX, is restricted to the germline, but these molecules are also broadly upregulated in various tumors. Expression of either/or both NY-ESO-1 or and MAGE-A4 has been observed in >50% of primary synovial sarcoma specimens, with NY-ESO-1 expression correlating with better 5-year overall survival rates. Varying degrees of NY-ESO-1 expression, and co-expression with MAGE-A4, has also been observed in myxoid LPS, osteosarcomas, pleomorphic LPS and chondrosarcomas, highlighting CTAs as appealing targets for ACT in sarcoma. In a pilot trial, treatment with transgenic T cells targeting NY-ESO-1, in combination with interleukin (IL)-2, resulted in objective clinical responses in 60% of refractory synovial sarcoma patients, which was later corroborated in metastatic synovial sarcoma where treatment led to tumor regression in 50% of patients. Promisingly, patients expressing both low or high levels of NY-ESO-1 responded to therapy.

**CAR T Cells**

Differently than TCRs, that can only recognize MHC class I restricted peptides, CARs can target any protein expressed on the surface of tumor cells, and are therefore a primary focus for ACT. The identification of tumor-specific antigens for CAR targeting has historically been a hurdle to the implementation of these therapies in solid tumors, but recent preclinical studies have identified promising targets in sarcoma, including GD2 expressed in human osteosarcoma, rhabdomyosarcoma (RMS) and EW sarcoma, B7-H3 (CD276) expressed in pediatric solid sarcomas, and Platelet-derived growth factor receptor α expressed in RMS and HER2-expressed in osteosarcoma (figure 1).

However, the promising in vitro results showing that GD2-specific CAR T cells lyzed GD2+ human sarcoma cell lines and patient-derived primary osteosarcoma tumor cells, have not been met with successful translation in preclinical models, where GD2-specific CAR T cells failed to control growth of xenograft tumor models. However, the administration of drugs that target MDSCs or the protumorigenic factor HFG increased the therapeutic efficacy of GD2-specific CAR T cells, suggesting that in sarcoma CAR T cells need additional help to overcome the barriers in the TME. To partially address this point, alternative effectors to T cells have been tested as recipients of the CAR vector, including cytokine induced killers cells, a heterogeneous population comprised of natural killer T cells (NKT), cytotoxic T cells and NK cells, which showed promising results in vitro and in vivo.

The first CAR T cell therapy evaluated in sarcoma patients (16 osteosarcomas, 1 EW sarcoma) was a first generation HER2-targeting CAR. This phase I study showed safety and partial efficacy with 4/17 patients with stable disease for up to 14 months. CAR-T cells were detected in tumors of 2/2 patients examined, even if no radiologic complete responses were observed. To improve on these encouraging results, clinical studies are now evaluating targeting different antigens (eg, receptor tyrosine kinase-like orphan receptor 2, CD133, GD-2, Mucl and CD117) and the use of second-generation, third-generation and fourth-generation CARs (NCT03618381, NCT03356782, NCT01953900). Ongoing ACT clinical trials using endogenous, transgenic or CAR T cells are listed in table 1.

**NK cells**

Alternatively to T cells, NK cells can be used in ACT, as established successfully in xenograft sarcoma mouse models and in a first-in-dog clinical trial. Ten dogs with advanced osteosarcoma received radiation in combination with intravenous NK cell transfer. Treatment was overall well tolerated and five patients remained metastasis-free at the 6-month primary endpoint. Most clinical trials involving adoptive NK cell therapy are investigating their use for hematological malignancies, however, studies are emerging for their use in solid tumors. Clinical trials for NK cell therapy with published results are reviewed here. There are several active and recruiting clinical trials investigating the use of NK cell therapy in sarcoma (table 1). A phase I trial (NCT02890758) is evaluating the use of universal donor NK cells for patients with various cancer indications including STS, RMS and EW. Usually for NK cell therapy, HLA-matched donor NK cells are used. In this trial, unmatched healthy donor NK cells are used in combination with ALT803, a protein that supports NK cell growth and viability (figure 1). Interestingly, aerosol delivery of IL-2, in combination with adoptive NK cell transfer in preclinical models, showed enhanced therapeutic effects of NK cells in delaying or completely eliminating lung metastasis in a model of osteosarcoma. Considering the approval of IL-2 for other cancers, aerosol delivery of IL-2 in osteosarcoma patients should be considered for ACT.

**Vaccines**

Therapeutic cancer vaccines are designed to stimulate a patient’s immune system against cancer and typically target a tumor antigen. Many approaches can be taken to elicit this anti-tumor immune response, such as a peptide vaccine incorporating tumor antigen peptide(s) combined with an adjuvant. A phase II trial of a trivalent ganglioside vaccine (GM2, GD2 and GD3) in 136 sarcoma patients observed serological GM2-specific and GD2-specific responses in 98% of treated patients, however, no difference in progression-free survival was observed between patient cohorts (NCT01141491) (figure 1). Similarly, in a study using a 9-mer peptide spanning the SYT-SSX junction in 21 synovial sarcoma patients, 7 patients showed a twofold increase in SYT-SSX expression of cancer testis antigens (CTAs), including MAGE, NY-ESO-1 and SSX, is restricted to the germline, but these molecules are also broadly upregulated in various tumors. Expression of either/or both NY-ESO-1 or and MAGE-A4 has been observed in >50% of primary synovial sarcoma specimens, with NY-ESO-1 expression correlating with better 5-year overall survival rates. Varying degrees of NY-ESO-1 expression, and co-expression with MAGE-A4, has also been observed in myxoid LPS, osteosarcomas, pleomorphic LPS and chondrosarcomas, highlighting CTAs as appealing targets for ACT in sarcoma. In a pilot trial, treatment with transgenic T cells targeting NY-ESO-1, in combination with interleukin (IL)-2, resulted in objective clinical responses in 60% of refractory synovial sarcoma patients, which was later corroborated in metastatic synovial sarcoma where treatment led to tumor regression in 50% of patients. Promisingly, patients expressing both low or high levels of NY-ESO-1 responded to therapy.

**CAR T Cells**

Differently than TCRs, that can only recognize MHC class I restricted peptides, CARs can target any protein expressed on the surface of tumor cells, and are therefore a primary focus for ACT. The identification of tumor-specific antigens for CAR targeting has historically been a hurdle to the implementation of these therapies in solid tumors, but recent preclinical studies have identified promising targets in sarcoma, including GD2 expressed in human osteosarcoma, rhabdomyosarcoma (RMS) and EW sarcoma, B7-H3 (CD276) expressed in pediatric solid sarcomas, and Platelet-derived growth factor receptor α expressed in RMS and HER2-expressed in osteosarcoma (figure 1).

However, the promising in vitro results showing that GD2-specific CAR T cells lyzed GD2+ human sarcoma cell lines and patient-derived primary osteosarcoma tumor cells, have not been met with successful translation in preclinical models, where GD2-specific CAR T cells failed to control growth of xenograft tumor models. However, the administration of drugs that target MDSCs or the protumorigenic factor HFG increased the therapeutic efficacy of GD2-specific CAR T cells, suggesting that in sarcoma CAR T cells need additional help to overcome the barriers in the TME. To partially address this point, alternative effectors to T cells have been tested as recipients of the CAR vector, including cytokine induced killers cells, a heterogeneous population comprised of natural killer T cells (NKT), cytotoxic T cells and NK cells, which showed promising results in vitro and in vivo.

The first CAR T cell therapy evaluated in sarcoma patients (16 osteosarcomas, 1 EW sarcoma) was a first generation HER2-targeting CAR. This phase I study showed safety and partial efficacy with 4/17 patients with stable disease for up to 14 months. CAR-T cells were detected in tumors of 2/2 patients examined, even if no radiologic complete responses were observed. To improve on these encouraging results, clinical studies are now evaluating targeting different antigens (eg, receptor tyrosine kinase-like orphan receptor 2, CD133, GD-2, Mucl and CD117) and the use of second-generation, third-generation and fourth-generation CARs (NCT03618381, NCT03356782, NCT01953900). Ongoing ACT clinical trials using endogenous, transgenic or CAR T cells are listed in table 1.

**NK cells**

Alternatively to T cells, NK cells can be used in ACT, as established successfully in xenograft sarcoma mouse models and in a first-in-dog clinical trial. Ten dogs with advanced osteosarcoma received radiation in combination with intravenous NK cell transfer. Treatment was overall well tolerated and five patients remained metastasis-free at the 6-month primary endpoint. Most clinical trials involving adoptive NK cell therapy are investigating their use for hematological malignancies, however, studies are emerging for their use in solid tumors. Clinical trials for NK cell therapy with published results are reviewed here. There are several active and recruiting clinical trials investigating the use of NK cell therapy in sarcoma (table 1). A phase I trial (NCT02890758) is evaluating the use of universal donor NK cells for patients with various cancer indications including STS, RMS and EW. Usually for NK cell therapy, HLA-matched donor NK cells are used. In this trial, unmatched healthy donor NK cells are used in combination with ALT803, a protein that supports NK cell growth and viability (figure 1). Interestingly, aerosol delivery of IL-2, in combination with adoptive NK cell transfer in preclinical models, showed enhanced therapeutic effects of NK cells in delaying or completely eliminating lung metastasis in a model of osteosarcoma. Considering the approval of IL-2 for other cancers, aerosol delivery of IL-2 in osteosarcoma patients should be considered for ACT.

**Vaccines**

Therapeutic cancer vaccines are designed to stimulate a patient’s immune system against cancer and typically target a tumor antigen. Many approaches can be taken to elicit this anti-tumor immune response, such as a peptide vaccine incorporating tumor antigen peptide(s) combined with an adjuvant. A phase II trial of a trivalent ganglioside vaccine (GM2, GD2 and GD3) in 136 sarcoma patients observed serological GM2-specific and GD2-specific responses in 98% of treated patients, however, no difference in progression-free survival was observed between patient cohorts (NCT01141491) (figure 1). Similarly, in a study using a 9-mer peptide spanning the SYT-SSX junction in 21 synovial sarcoma patients, 7 patients showed a twofold increase in SYT-SSX expression...
Figure 1  Harnessing the immune system against sarcoma. (1) Immune checkpoint inhibitors restore the ability of immune cells (e.g., cytotoxic T cells) to mediate anti-cancer immunity. (2) Autologous T cells transduced with a T cell receptor specific for tumor antigens are expanded and infused in patients where they exert cytotoxic functions. (3) CAR T cells against several sarcoma specific antigens can be designed to further boost adoptive T cell therapy. (4) Universal donor NK cells administered with ALT803 may enhance the therapeutic effects of NK cells. (5) Therapeutic cancer vaccines are designed to stimulate a patient’s immune system against cancer and typically target a tumor antigen. Vaccine approaches evaluated in sarcoma include peptide vaccines, or dendritic cell vaccines loaded with tumor lysate or pulsed with antigenic peptide. (6) Oncolytic viruses T-VEC and Pexa-VEC are being evaluated in sarcoma, and promote tumor destruction by direct lysis of tumor cells, transgene expression (e.g., GM-CSF) and stimulation of adaptive and innate immune responses. (7) Anti-tumor immunity can be promoted by antibodies targeting tumor antigens (e.g., GD2) eliciting antibody-mediated or complement-mediated cytotoxicity. (8) Molecules preventing polarization of anti-cancer M1 macrophages to tumor-promoting M2 macrophages can potentiate anti-cancer immunity in sarcoma. CAR, chimeric antigen receptors; CSF1R, colony stimulating factor 1 receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor; NK, natural killer; T-VEC, talimogene laherparepvec.
The lack of therapeutic response using the aforementioned peptide vaccine approaches in sarcoma prompted the development of alternative vaccination strategies. Dendritic cell (DC) vaccines consist of patient-derived DCs loaded with autologous tumor lysate or tumor antigens ex vivo. An ongoing phase I study is investigating a tumor-lysate loaded monocyte-derived DC vaccine in advanced sarcoma and neuroblastoma pediatric patients (EudraCT 2014-003388-39). Forty-seven pediatric patients have been enrolled in the study, 11 with sarcoma. The treatment was safe and immunomonitoring of nine sarcoma patients (two EW sarcoma, four osteosarcoma, one synovial sarcoma and two RMS) revealed enhanced ex vivo T cell responses on vaccination. 55, 57 In another phase I/II trial, a tumor lysate-pulsed DC vaccine was evaluated in 37 patients with bone or STS. No adverse effects were associated with treatment, and immunological responses to the treatment included significantly elevated interferon (IFN-γ) and IL-12 in the serum, suggesting that this vaccine activated the patient’s immune response. However, despite evidence of boosted immunity, only 1/35 patients achieved a partial response to therapy. 58

Another approach to DC-vaccination is to peptide-pulse DCs with a tumor antigen, forgoing the need for invasive surgical resection of tumor to isolate tumor lysates. One pilot study, including patients with advanced sarcoma that have progressed on standard-of-care chemotherapy and radiation (including synovial sarcoma, osteosarcoma and LPS), uses NY-ESO-1 peptide-pulsed DCs in combination with IL-2 and autologous lymphocytes transduced with a NY-ESO-1-specific T-cell receptor, with or without CTLA-4 blockade (NCT02070406, NCT01697527). 60 Treatments were safe but, only one synovial sarcoma patient (receiving treatment without ipilimumab) progressed to complete response, despite evidence of anti-tumor activity determined by positron emission tomography imaging in 6 out of 10 patients. This lack of long-lasting response to therapy in the majority of patients could be attributed to the fact that the adoptively transferred cells were found to be short lived in peripheral circulation.

Table 1: Ongoing sarcoma immunotherapy clinical trials

<table>
<thead>
<tr>
<th>Paradigm</th>
<th>Intervention</th>
<th>Disease</th>
<th>Status</th>
<th>Clinical trial ID</th>
<th>Locations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adoptive cell transfer</td>
<td>TIL IL-2 Fludarabine Cyclophosphamide NY-ESO-1 T cells</td>
<td>High grade STS</td>
<td>Phase I, Recruiting</td>
<td>NCT04052334</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAR T cells</td>
<td>Anti-GD2 (C7R-GD2.CAR) T cells Fludarabine Cyclophosphamide</td>
<td>Relapsed OS, relapsed Ewing’s sarcoma, relapsed RMS</td>
<td>Phase I, Recruiting</td>
<td>NCT03635632</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>Autologous anti-HER-2 CAR T Fludarabine Cyclophosphamide</td>
<td>STS</td>
<td>Phase I, Active</td>
<td>NCT00902044</td>
<td>USA</td>
</tr>
<tr>
<td>Vaccines</td>
<td>Tumor lysate loaded DC Vaccine Gemcitabine Imiquimod</td>
<td>STS, Bone sarcoma</td>
<td>Phase I, Active</td>
<td>NCT01803152</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>GVAX</td>
<td>Clear Cell Sarcoma, Alveolar Soft Part sarcoma</td>
<td>Phase I, Active</td>
<td>NCT00258687</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>MVA expressing p53</td>
<td>STS</td>
<td>Phase I, Active</td>
<td>NCT02432963</td>
<td>USA</td>
</tr>
<tr>
<td>Adoptive NK cell therapy</td>
<td>NK cell infusion HSCT</td>
<td>RMS</td>
<td>Phase I, II, Completed</td>
<td>NCT01386619</td>
<td>Germany Switzerland</td>
</tr>
<tr>
<td></td>
<td>NK cell infusion and recombinant IL-15</td>
<td>Sarcoma</td>
<td>Phase I, Completed</td>
<td>NCT01875601</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>Expanded, activated NK cells</td>
<td>Ewing Sarcoma, RMS</td>
<td>Phase I, II, Recruiting</td>
<td>NCT02409576</td>
<td>Singapore</td>
</tr>
<tr>
<td></td>
<td>NK cell infusion HSCT</td>
<td>Ewing Sarcoma, OS, RMS, STS</td>
<td>Phase II, Active, not recruiting</td>
<td>NCT01807468</td>
<td>South Korea</td>
</tr>
</tbody>
</table>

CAR, chimeric antigen receptor; DC, dendritic cell; GD2, disialoganglioside; HSCT, hematopoietic stem cell transplantation; IL-15, interleukin 15; MVA, modified vaccinia Ankara; OS, osteosarcoma; RMS, rhabdomyosarcoma; STS, soft-tissue sarcoma; TIL, tumor infiltrating lymphocyte.
and generated a high anti-EDB antibody titer compared with controls.61 This promising technology can be used for the induction of immune responses against other tumor-antigens or components of the TME and may be an improvement on traditional peptide vaccines.

Although cancer vaccines for sarcoma appear to be safe and result in an immunological response in most of the patients, limited improvement in clinical outcome of patients suggests that many modifications need to be made to attain better therapeutic outcomes. Additional clinical trials using vaccines for sarcoma are listed in table 1.

**Oncolytic viruses**

OVs are self-propagating viruses that selectively infect and kill tumor cells. In addition to their direct effects, OVs promote virally encoded transgene expression (eg, cytokines), cause vascular collapse, and generally alter the TME to stimulate antitumor immune responses. Pointing toward the possibility of using OVs in sarcoma immunotherapy, a comprehensive study comparing the efficacy of four OV head to head in a panel of sarcoma cell lines showed that the rhabdoviruses Maraba and vesicular stomatitis virus (VSV) were highly effective at broadly killing sarcoma cell lines, while Reovirus and herpes simplex virus type I (HSV) were only effective in EW sarcoma cell lines, and synovial sarcoma (SW982) was resistant to infection by all viruses tested.62 This result corroborates previous findings that SW982 cells are refractory to infection by a different VSV strain.63 Results obtained with cell lines were corroborated using ex vivo infection of freshly collected human sarcoma samples where Maraba successfully infected ~95% of samples. Encouragingly, mice injected subcutaneously with the sarcoma cell line S180 responded to Maraba treatment, revealing Maraba MG1 as a promising candidate for sarcoma immunotherapy.63

When tested in vitro, H-1PV, a rodent protoparvovirus non-pathogenic in humans, effectively infected human synovial sarcoma (Sw-R), a subtype that is resistant to VSV infection, as well as osteosarcoma and EW sarcoma cell lines.53-66 However, when evaluated as a therapeutic in a xenograft model, one dose of H-1PV did not lead to tumor regression or increased overall survival, although the lack of therapeutic effect could be attributed to insufficient dosing or owing to the use of immunodeficient mice in this study as OVs work, at least in part, by inducing anti-tumor immunity.66

There is a rich pipeline of OVs in pre-clinical evaluation and many have progressed to clinical trials. Few have gained regulatory approval, such as the genetically engineered HSV-1 Talimogene laherparepvec (T-VEC; Imlygic), which has specific virus attenuating mutations and encodes granulocyte-macrophage colony-stimulating factor (GM-CSF) in order to promote anti-tumor immune responses.67 Imlygic, was approved for treatment of advanced melanoma by the FDA in 2015. T-VEC in melanoma has led to its evaluation in other solid malignancies, including sarcoma (figure 1).

Two phase II clinical trials evaluating T-VEC are currently recruiting. The first is determining the combination of T-VEC and radiation therapy as a preoperative treatment for patients with newly diagnosed local STS (NCT02923778); the second is evaluating the efficacy of intratumoral administered T-VEC in locally advanced cutaneous angiosarcoma. Another oncolytic HSV-1 (HSV-1716) was tested in phase I clinical trial in patients with solid tumors that included eight pediatric patients with RMS, EW sarcoma, osteosarcoma, MPNST or chordoma and two adult patients with chondrosarcoma or EW sarcoma (NCT00931931). Unfortunately, while the virus was found safe, no objective responses were observed, suggesting that HSV-1 may not be ideally suited for these sarcoma subtypes.68

Pexastimogene devacirepvec (Pexa-Vec) is derived from a Wyeth vaccinia virus strain and engineered to target cancer cells. Similar to Imlygic, it is armed with GM-CSF. In a phase I trial, Pexa-Vec was safe when administered intratumorally in a cohort of RMS, Ewings sarcoma, osteosarcoma, and other STS pediatric patients (NCT01169584). A phase I/II study of Pexa-Vec in combination with metronomic cyclophosphamide in patients with advanced STS and advanced breast cancer is currently recruiting (NCT02630368).

Overall, preclinical studies suggest OV could be promising immunotherapies for the treatment of sarcoma. However, this remains to be corroborated in clinical studies. So far, OVs have had limited success as monotherapies and it is likely that OVs will require use in combination with other modalities that can overcome known resistance mechanisms, including innate antiviral responses and immunological resistance, for example.69-72 Additionally, some OVs may be more effective than others depending on the sarcoma subtypes as indicated from comparative in vitro studies.62

**Cancer-targeted antibodies**

Anti-tumor immunity can be promoted by antibodies targeting tumor antigens eliciting antibody-mediated or complement-mediated cytotoxicity. Surface disialoganglioside (GD2), a glycosphingolipid involved in cell proliferation, is also a known tumor associated antigen, most notably expressed in neuroblastoma, melanoma and half of all osteosarcomas and STS.73 Widespread distribution of GD2 in neuroblastoma prompted preclinical development of GD2-targeting mAbs and led to phase I trials of humanized 3F8 (hu3F8) and FDA approval of the mAb ch14.18, also known as dinutuximab, in 2015 (figure 1).74 75 GD2 is expressed in ~50% of osteosarcomas and STS’, although with significant intratumoral heterogeneity, therefore, there is a potential of expanding the use of anti-GD2 for osteosarcoma, with clinical trials currently ongoing79 75 76 (NCT02502786, NCT02484443).
**Targeting macrophages**

The polarization of macrophages associated to the tumor (TAMs), either directly infiltrating the TME or deriving from monocytes, is a key determinant of the outcome of anti-tumor immunity. In a broad sense, M1 macrophages typically promote anti-cancer immunity whereas M2 macrophages are usually associated with worse prognosis given they promote immunosuppression, tumor angiogenesis and metastasis. Therapies that indirectly prevent macrophage polarization toward an M2 phenotype are currently being tested in preclinical models. For example, treatment of MCA-205 fibrosarcoma mouse model with anti-angiogenic peptide led to a reduction of M2-polarized macrophages, which was important for the therapeutic effect of the peptide. In another study, TAMs were directly targeted by treating sarcoma-bearing mice with nanoparticles containing zolendronate leading to significant tumor regression. A more favorable TAM polarization was instead achieved using TLR2 agonists that increased the M1/M2 ratio in sarcoma-bearing mice leading to decreased tumor growth.

The CD47-SIRPα pathway promotes tumor immune escape by inhibiting macrophage phagocytosis (do not eat me signal) and is an appealing target for immunotherapy as revealed by studies showing that: (1) an abundance of SIRPα in TAMs was associated with worse prognosis in patients with synovial sarcoma and myxofibrosarcoma; and (2) high expression of CD47 correlated with poor survival in osteosarcoma patients. In an osteosarcoma mouse model, mice treated with a CD47 blocking antibody, alone or in combination with doxorubicin, had reduced tumor burden. Although no clinical trials are currently ongoing in sarcoma for monoclonal antibodies targeting CD47, targeting of the same pathway is under clinical evaluation in a phase I trial (NCT02890368) in sarcoma for monoclonal antibodies binding to activating Fc receptors. As a single agent, IFN-α cytokine therapy is most successful at high doses and in Kaposi’s sarcoma patients with higher baseline CD4+ T cell counts but is commonly used in conjunction with chemotherapies. With the advent of anti-retroviral therapy, IFN-α began to be used in lower doses in combination with these anti-retrovirals. Overall, the anti-proliferative, anti-angiogenic and anti-viral effects of IFN-α therapy are thought to induce tumor regression in HIV-induced Kaposi’s sarcoma. However, liposomal doxorubicin and paclitaxel are still the front line treatment for Kaposi’s sarcoma.

The transforming growth factor-beta (TGF-β) signaling pathway is known to be dysregulated in many cancers and the cytokine is notorious for its dual role of both tumor promoting and tumor suppressing activities in late stage and early-stage cancers, respectively. In the case of osteosarcoma, TGF-β was found to be increased in the serum of patients compared with healthy controls and is now seen as a driver of metastatic potential in this cancer. Furthermore, in vitro studies revealed that treatment of osteosarcoma cell lines with TGF-β induced epithelial-mesenchymal transition, providing further evidence of its role in stimulating metastasis. Decreasing levels of serum TGF-β is also seen in EW sarcoma and RMS patients during remission, and as such may have prognostic value. In light of these findings, if the key role of TGF-β is elucidated, there is potential in inhibiting the key components of the TGF-β pathway as a therapeutic strategy for osteosarcoma, EW sarcoma and RMS. Clinical trials of TGF-β ligand and receptor inhibitors are ongoing for many advanced stage carcinomas, melanomas and gliomas and should, therefore, be given considerable thought for its use in osteosarcoma.

**Combination therapies**

Since ICB has shown limited efficacy as a monotherapy for sarcoma, numerous studies are investigating ICB therapy in combination with other treatments. More specifically, one study evaluated NV-ESO-1 specific CD8 T cells of patients with NV-ESO-1+ positive tumors and found that these cells are enriched for expression of LAG-3 and PD-1. To address upregulation of inhibitory molecules, an ongoing study is evaluating a vaccine targeting NV-ESO-1 (called CMB305) in combination with anti-PDL1 (atezolizumab) in sarcoma (NCT02609984). In the context of OV, Newcastle disease virus (NDV) for treatment of syngeneic tumor models of melanoma induced PD-L1 upregulation of infected cells, and inhibited effector functions of tumor infiltrated T cells. Similarly, oncolytic vaccinia virus treatment of murine models of colon and ovarian cancer induced PD-L1 expression in canccer and immune cells. Suggesting immune checkpoints are a potential contributor to resistance to OV therapy, the combination of NDV and other OVs with ICB has shown to provide therapeutic benefit in various preclinical models. A phase 2 trial (NCT03069378) HIV-induced Kaposi’s sarcoma, a malignancy of blood and lymph vessels caused by the human herpesvirus 8. As a single agent, IFN-α cytokine therapy is most successful at high doses and in Kaposi’s sarcoma patients with higher baseline CD4+ T cell counts but is commonly used in conjunction with chemotherapies. With the advent of anti-retroviral therapy, IFN-α began to be used in lower doses in combination with these anti-retrovirals. Overall, the anti-proliferative, anti-angiogenic and anti-viral effects of IFN-α therapy are thought to induce tumor regression in HIV-induced Kaposi’s sarcoma. However, liposomal doxorubicin and paclitaxel are still the front line treatment for Kaposi’s sarcoma.
recently investigated the combination of pembrolizumab with T-VEC. The overall response rate was 35% (7/20) with no complete responses and 7 partial responses. The partial responses were observed in patients with UPS, myxofibrosarcoma, epithelioid sarcoma, cutaneous angiosarcoma and an unclassified sarcoma. Also, the TIL score and PD-L1 expression was higher in responders compared with the refractory group. An expansion cohort for this study is underway for patients with UPS, myxofibrosarcoma and angiosarcoma. A multi-center pilot study (NCT03282344) is currently evaluating the safety and efficacy of treating refractory sarcoma patients with nivolumab and NKTR-214, an IL-2 pathway agonist. Preliminary results from 50 enrolled patients showed partial responses in patients with UPS (2/10), dedifferentiated chondrosarcoma (1/10) and leiomyosarcoma (1/10) and no responders from DDLPS and osteosarcoma patients. A phase II multi-arm study (NCT02815995) investigated the benefit of combining durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4). Their primary endpoint which was progression-free survival at 3 months, was reached in 51% of patients (n=57). It was also observed that a high immune infiltration score could predict clinical benefit. Many of the combination ICB trials include patients with advanced sarcomas who are refractory to standard treatment and/or did not respond to previous ICB monotherapy. Due to the nature of these studies, monotherapy groups are not included, which can make it difficult to determine which component of the combination treatment improved the clinical outcome.

Predicting response to ICB immunotherapy

The clinical studies discussed show that there is a heterogeneous response of sarcoma to checkpoint blockade. Despite the progress of the most promising immunotherapeutic approach, ICB, only a small proportion of patients given this treatment have clinical responses. One consideration is that patient selection for ICB treatment is generally performed in a single analyte manner, whereby patients are selected based on expression levels of immune inhibitory molecules being targeted. As we increase our understanding of the immune mechanisms at play within the tumor, it is evident that this analysis provides an incomplete picture of the dynamic tumor immune microenvironment that contributes to the efficacy of ICB therapy. To this end, several studies have sought to establish predictive biomarkers using multigene analysis to guide treatment.

A seminal study identified an immune-related signature correlating with clinical responses from different clinical studies using pembrolizumab (KEYNOTE-180, KEYNOTE-181, KEYNOTE-158), and developed a scoring algorithm predicting patients’ response to pembrolizumab based on tumor expression of 18 IFN-γ-related immune genes. The Tumor Inflammation Signature (TIS) score measures activated but suppressed adaptive immune responses within tumors. Notably, this score has been retrospectively applied to clinical trial data, and high scores were found to be associated with response to pembrolizumab, further supporting the use TIS to guide patient selection in future ICB clinical trials for sarcoma.

Another group developed a new immune-based classification of STS based on the composition of the tumor immune microenvironment determined from gene expression profiles, and stratified 608 STS into one of five SIGs with highly distinct immune profiles. Patients with tumors classified in the immune high group—characterized by high expression of genes specific to CD8+ T cells, NK cells, B cells and tertiary lymphoid structures, exhibited the largest response rate to PD-1 blockade therapy (in comparison to tumors with different immune class) in a phase I clinical trial of pembrolizumab in STS (SARC028). This study highlights the heterogeneity of sarcoma, and the need for increased understanding of immune status of sarcomas to select appropriate immunotherapeutic treatments for patients. Altogether, these data show that similarly to other cancers, in sarcoma a T cell-inflamed TME, characterized by cytotoxic effector lymphoid functions and active IFN-γ signaling, are features of patients responding to PD-1 blockade. Further elucidating the tumor immune microenvironment of sarcoma subtypes will refine patient eligibility criteria for sarcoma immunotherapy trials, and further investigation will be necessary to predict patient outcome in response to other immunotherapeutic approaches discussed in this review.

CONCLUSION

Recent research has highlighted an opportunity to harness the immune response to develop immunotherapies against sarcoma. There is currently a wealth of immunotherapy strategies that can be employed which include: ICB, ACT, conventional vaccines, OV and targeting of innate immune mechanisms such as macrophages and cytokine modulation therapies. It is often difficult to navigate which therapeutic approach is likely to be more successful. Here, we reviewed preclinical and clinical studies that have focused on investigating which immunotherapy can succeed in treating the different sarcoma indications. While it is difficult to adequately capture the complexity of sarcomas, it appears combination therapies involving ICBs is likely the path forward. As described above, ICB combinations with OV’s, antigen targeting vaccines and ACT will provide a holistic path towards treatment. Disease progression and disease recurrence, both prevalent complications of many sarcomas, should also be taken into consideration when choosing a therapy. However, each subtype will nevertheless require stringent characterization of its immune components, biomarkers and response predictors to select an optimal therapy.

Correction notice This article has been corrected since it was first published. The overall response rate reported for reference 97 (Kelly et al) was cited incorrectly and has now been amended.
Twitter Michele Ardolino @qfkc

Contributors HKB, AJ, SC-K wrote the manuscript. JW and CN edited the manuscript. JSD and MA wrote the manuscript and supervised the preparation of the review.

Funding Sarcoma research in the Ardolino Lab is funded by CIHR (to MA) and a University of Ottawa Translational Research Grant (to MA and CN). Sarcoma research in the Diallo lab is funded by the Discovery’s Flutter foundation, BioCanRx, the Ontario Molecular Pathology Research Network (OMPRN) and a CIHR New Investigator award (Infection and Immunity).

Competing interests J-SD is an inventor on patents licensed to Turnstone Biologics, which is commercializing oncolytic Maraba virus. J-SD has patents licensed and also holds equity in Virica Biotech, which is developing oncolytic virus platforms.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the work is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Michele Ardolino http://orcid.org/0000-0003-4114-0985

REFERENCES
25. D’Angelo SP, Melchiori L, Merchant MS, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-


Correction: Immunotherapy for sarcomas: new frontiers and unveiled opportunities


This article has been corrected since it was first published. The overall response rate for the trial by Kelly et al (reference 97) was cited incorrectly and has now been corrected to 35% (7/20).

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.